These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29522278)

  • 1. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
    Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
    Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
    Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
    Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    Kim JH; Kim WS; Park C
    BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
    J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
    Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
    Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.
    Faia K; White K; Murphy E; Proctor J; Pink M; Kosmider N; McGovern K; Kutok J
    PLoS One; 2018; 13(8):e0200725. PubMed ID: 30067771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
    Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
    J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
    Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
    Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
    Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
    Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role of phosphatidylinositol 3-kinase/Akt pathway on cell growth and lytic cycle of Epstein-Barr virus in the Burkitt's lymphoma cell line, P3HR-1.
    Mori T; Sairenji T
    Virus Genes; 2006 Jun; 32(3):327-34. PubMed ID: 16732486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines.
    Park GB; Song H; Kim YS; Sung M; Ryu JW; Lee HK; Cho DH; Kim D; Lee WJ; Hur DY
    Immunology; 2009 Nov; 128(3):360-8. PubMed ID: 20067536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.
    Hatton O; Lambert SL; Krams SM; Martinez OM
    PLoS One; 2012; 7(8):e42610. PubMed ID: 22880054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr Virus-Positive Lymphomas Exploit Ectonucleotidase Activity To Limit Immune Responses and Prevent Cell Death.
    Lange PT; Damania B
    mBio; 2023 Apr; 14(2):e0345922. PubMed ID: 36786572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
    Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
    Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
    Feng WH; Hong G; Delecluse HJ; Kenney SC
    J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
    Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
    J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.